Wednesday, July 8, 2026

Patent intelligence · US

US 12295362

Formulations and processes for CAR T cell drug products

granted A61KA61K40/11A61K40/31A61K40/4211
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 19
Applicant portfolio 16
Patent details — US 12295362
Jurisdiction
US
Status
granted
Grant date
May 13, 2025
Expiration
May 8, 2045
Claims
20
CPC classes
A61K, A61K40/11, A61K40/31, A61K40/4211
View on Google Patents ↗

Quick answer

US 12295362 (Formulations and processes for CAR T cell drug products) is held by Allogene Therapeutics, Inc.. Status: granted. Granted May 13, 2025. Expires May 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K40/11, A61K40/31, A61K40/4211

More from Allogene Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12404315

    Protease-activating CD45-gate CAR

    Allogene Therapeutics, Inc. · Expires Aug 28, 2045

    granted
  2. US 12365873

    Methods for transducing immune cells

    Allogene Therapeutics, Inc. · Expires Jul 17, 2045

    granted
  3. US 12221462

    Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

    Allogene Therapeutics, Inc. · Expires Feb 6, 2045

    granted
  4. US 12215347

    Chimeric antigen receptors with enhanced signaling and activities and uses thereof

    Allogene Therapeutics, Inc. · Expires Jan 30, 2045

    granted
  5. US 12163153

    Methods of manufacturing allogeneic CAR T cells

    Allogene Therapeutics, Inc. · Expires Dec 5, 2044

    granted
  6. US 12163169

    Inducible chimeric cytokine receptors

    Allogene Therapeutics, Inc. · Expires Dec 5, 2044

    granted
  7. US 12104188

    Modified caspase-9 polypeptides and methods of use thereof

    Allogene Therapeutics, Inc. · Expires Sep 26, 2044

    granted

Frequently asked questions

What is US patent 12295362?

US 12295362 (Formulations and processes for CAR T cell drug products) is held by Allogene Therapeutics, Inc.. Status: granted. Granted May 13, 2025. Expires May 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12295362?

Allogene Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.

When does US 12295362 expire?

Our index shows an expiration date of May 8, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.